Aimcad Biotech Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 03-07-2024
- Paid Up Capital ₹ 0.50 M
as on 03-07-2024
- Company Age 11 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.00 M
as on 03-07-2024
- Revenue 3.90%
(FY 2022)
- Profit 28.21%
(FY 2022)
- Ebitda -20.90%
(FY 2022)
- Net Worth 23.61%
(FY 2022)
- Total Assets -3.90%
(FY 2022)
About Aimcad Biotech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹7.00 M.
Shyam Keshari, Ravi Pandey, Priyanka Keshari, and One other member serve as directors at the Company.
- CIN/LLPIN
U74120MH2013PTC272456
- Company No.
272456
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 May 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Aimcad Biotech Private Limited offer?
Aimcad Biotech Private Limited offers a wide range of products and services, including Business Planning and Management, Business Consultant, Content Writing Service, Research Development Services, Medical Surgery & Treatment Centres, Medical Treatment Services, Antibiotic Tablets & Capsules, Azithromycin Tablets.
Who are the key members and board of directors at Aimcad Biotech?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shyam Keshari  | Director | 03-Sep-2013 | Current |
| Ravi Pandey | Director | 27-May-2013 | Current |
| Priyanka Keshari | Director | 22-Oct-2013 | Current |
| Ruby Pandey | Director | 28-Aug-2014 | Current |
Financial Performance of Aimcad Biotech.
Aimcad Biotech Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 3.9% increase. The company also saw a substantial improvement in profitability, with a 28.21% increase in profit. The company's net worth Soared by an impressive increase of 23.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aimcad Biotech?
In 2020, Aimcad Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 29 Jan 2014 | ₹7.00 M | Open |
How Many Employees Work at Aimcad Biotech?
Unlock and access historical data on people associated with Aimcad Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aimcad Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aimcad Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
